In , Sakar Healthcare Ltd (Hospitals) is outperforming Nifty 500 with +26.1% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: Marketing Authorizations: 11 approved
“One of the most notable developments of this quarter has been the approval of our oncology facility as a manufacturing source for product supplies to the EU.”
What: Oncology Utilization: 20%
Impact: ₹1,000 Crores revenue potential
“If you consider oncology, it has just crossed 20% of the capacity utilization... we can look forward for INR1,000 crores with oncology plant.”
What: Export Revenue %: 70%
“The continued shift towards high-margin own brand exports, which now contribute over 70% of the revenue, has further enhanced profitability.”
What: Dossier Pipeline: 102 submitted
“Of the 211 oncology dossiers shared globally, 102 dossiers have now been submitted across partner markets.”
What: Oncology Revenue Share: 37% of H1 total
Impact: 500 bps margin expansion target
“Oncology if you see, almost we have doubled the sale what we had achieved last year... oncology is driving the overall revenue growth.”
What: Q3 EBITDA Margin of 26%
“EBITDA margins at 26%... supported by operating leverage and better product mix. Gross margins remained healthy at 49%.”
Earnings deceleration risks from management commentary
Trigger: Regulatory approvals are the primary bottleneck for commercializing the dossier pipeline.
Management view: Management is applying for slots in various EU countries to ensure a steady flow of approvals.
Monitor: regulatory
Trigger: Initial setup for new geographies involves complex regulatory and partner coordination.
Management view: Subsequent orders will have a reduced lead time of 75-90 days.
Monitor: logistics
Trigger: Revenue is increasingly denominated in foreign currencies as the company pivots to global markets.
Management view: Not explicitly detailed on call.
Monitor: fx
Key quotes from recent conference calls
“In the AGM, we did say about reaching INR280 crores revenue this year with about 25% EBITDA margin. [Previous Full Year Revenue guidance]”
“It can range from INR50 crores to INR100 crores that can be the potential of these products what we are currently managing. [Initiative: Oncology Tech Transfer (10 Molecules)]”
“Normal standard timeline is 210 working days for Europe for approval of any dossier... Once the query pops up, then there is a stop clock. [Risk (regulatory): HIGH]”
“For the first supply we need to get prepared with certain things... which include serialization of the products, then artwork of the products. [Risk (logistics): MEDIUM]”
Headline numbers from the latest earnings call
Revenue
₹7,034 Lakh
Why: Growth was driven by higher export volumes, improved scale utilization, and a continued shift towards high-margin own brand exports.
Revenue growth accelerated significantly in Q3 compared to the 34.6% YoY growth seen in Q2.
EBITDA
₹1,859 Lakh
Why: Profitability improved due to operating leverage and a better product mix, specifically from the oncology vertical.
Margins recovered to 26% from 20% in Q2 FY26 as one-time business development expenses subsided.
PAT
₹1,025 Lakh
Why: PAT growth was supported by increased contribution from oncology products and disciplined cost management.
PAT more than doubled sequentially, benefiting from lower tax provisions due to MAT credit availability.
Other Highlights
• Oncology revenue reached ₹31 Crores in Q3, with ₹19 Crores coming from exports.
• Gross margins remained healthy at 49% for the quarter.
• 11 oncology marketing authorizations received to date across Europe and emerging markets.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Oncology Revenue (Q3)
₹31 Crores
Why: Driven by the ramp-up of the Bavla facility and increased export authorizations.
Export Revenue % of Total
70%
Why: Strategic shift toward high-margin own brand exports in regulated markets.
Oncology Dossiers Submitted
102
Why: Aggressive filing strategy to build a long-term product pipeline.
Marketing Authorizations Received
11
Why: Authorizations cover key molecules like Imatinib and Tamoxifen across Europe.
Oncology Capacity Utilisation
20%
Why: Facility is in the early stages of commercial ramp-up.
Gross Margin
49%
Why: Improved efficiency and scale benefits across the oncology vertical.
Molecules in Tech Transfer
10
Why: Partnership with Accord/Intas for EU market supply.
Working Capital Cycle
135 days
Why: Improved efficiency in inventory management and order execution.
Annual Oncology Tablet Capacity
97 million
Annual High-Potent API Capacity
12.3 metric tons
Forward-looking targets from management for FY26-FY27
Revenue Growth Target
65%
OPM Guidance
30%
Capex Plan
₹39 Cr
₹280 Crores for FY26; 60-70% growth in Oncology for FY27
REAFFIRMED
₹39 Crores
Plant and machinery setup for oncology
Guidance Changes
Tax Rate: Normal slabs → 18-19%
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +63% | +12% | Accelerating |
| PAT (Net Profit) | +100% | +6% | Stable |
| OPM | 26.0% | -100 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Sakar Healthcare Ltd's latest quarterly results (Dec 2025) show
Sakar Healthcare Ltd's profit is growing with an stable trend.
Sakar Healthcare Ltd's revenue growth trend is accelerating.
Sakar Healthcare Ltd's operating margin is volatile.
Sakar Healthcare Ltd's long-term compounding rates
Sakar Healthcare Ltd's earnings growth is stable with improving on a sequential basis.
Sakar Healthcare Ltd's trailing twelve month (TTM) performance
Sakar Healthcare Ltd appears significantly overvalued based on our fair value analysis.
Sakar Healthcare Ltd's current PE ratio is 48.1x.
Sakar Healthcare Ltd's current PE is 48.1x.
Sakar Healthcare Ltd's price-to-book ratio is 4.0x.
Sakar Healthcare Ltd is rated Average with a fundamental score of 54/100. This score is calculated from objective financial metrics
Sakar Healthcare Ltd has a debt-to-equity ratio of N/A.
Sakar Healthcare Ltd's return ratios over recent years
Sakar Healthcare Ltd's operating cash flow is positive (FY2025).
Sakar Healthcare Ltd currently does not pay a significant dividend (yield 0.00%).
Sakar Healthcare Ltd's shareholding pattern (Mar 2026)
Sakar Healthcare Ltd's promoter holding has remained stable recently.
Sakar Healthcare Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Sakar Healthcare Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Sakar Healthcare Ltd has 6 key growth catalysts identified from recent earnings analysis
Sakar Healthcare Ltd has 3 key risks worth monitoring
In Q3 FY26, Sakar Healthcare Ltd's management highlighted
Sakar Healthcare Ltd's management has provided the following forward guidance for FY26-FY27
Sakar Healthcare Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Sakar Healthcare Ltd may be worth studying
Sakar Healthcare Ltd investment thesis summary:
Sakar Healthcare Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
